Rallybio Phase 2 trial of RLYB212 begins to tackle FNAIT in high-risk pregnancies
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company known for advancing innovative therapies for rare diseases, has commenced its Phase 2 clinical trial for RLYB212. The trial focuses on preventing HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare but life-threatening condition affecting pregnancies. The first screening phase to identify eligible pregnant women […]